Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

SinoMab Bioscience Ltd. (3681) Price & Analysis

3681 Stock Chart & Stats

HK$1.07HK$0.05(4.90%)
At close: 4:00 PM EDT
HKD 1HKD 1.1HKD 1.2HKD 1.33 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
HKD 1.00 - HKD 1.07
52-Week Range
HKD 0.96 - HKD 2.19
Previous Close
HKD 1.02
Volume
690.90K
Average Volume (3M)
645.38K
Market Cap
HKD 1.47B
Enterprise Value
HKD 1.43B
Total Cash (Recent Filing)
HKD 226.21M
Total Debt (Recent Filing)
HKD 266.78M
Price to Earnings (P/E)
―
Beta
1.00
Next Earnings
Mar 22, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Leverage

The 2025 improvement in leverage strengthens financial flexibility compared with the prior year and may reduce pressure from debt obligations. If maintained, a healthier capital structure could support continued clinical investment while lowering the risk that financing needs immediately overwhelm the business.

Narrower Losses

A narrower net loss indicates some progress in reducing the company’s earnings deficit, even though profitability remains distant. Sustained cost control or better operating execution could extend this improvement and preserve more capital for advancing antibody candidates toward approval and commercialization.

Multiple Monetization Routes

SinoMab has several potential paths to monetize its antibody platform rather than relying solely on direct product sales. Approved therapies could generate commercial revenue, while licensing and collaborations may provide milestone, royalty, or research income during development.

Bears Say

Persistent Unprofitability

持续 operating and net losses show that the business has not yet reached an economically self-sustaining stage. Continued deficits can consume capital needed for research and development, limit strategic flexibility, and make future progress dependent on improving commercialization or securing additional funding.

Structural Cash Burn

Consistently negative operating and free cash flow means the company does not currently fund its activities from internally generated cash. Even with a slower burn rate in 2025, ongoing dependence on external financing can constrain investment choices and increase funding risk.

Weak Commercial Scale

Minimal and recently zero revenue indicates that SinoMab has not yet established dependable commercial scale from its antibody assets. This leaves the company heavily reliant on funding and future development milestones, while delaying the point at which operating revenue can support recurring costs.

SinoMab Bioscience Ltd. News

3681 FAQ

What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$0.96 and its highest was HK$2.19 in the past 12 months.
What is SinoMab Bioscience Ltd.’s market cap?
SinoMab Bioscience Ltd.’s market cap is HK$1.47B.
When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SinoMab Bioscience Ltd.’s earnings last quarter?
SinoMab Bioscience Ltd. released its earnings results on Aug 31, 2026. The company reported -HK$0.105 earnings per share for the quarter.
Is SinoMab Bioscience Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does SinoMab Bioscience Ltd. pay dividends?
SinoMab Bioscience Ltd. does not currently pay dividends.
What is SinoMab Bioscience Ltd.’s EPS estimate?
SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SinoMab Bioscience Ltd. have?
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
SinoMab Bioscience Ltd. reported an EPS of -HK$0.105 in its last earnings report. Following the earnings report the stock price went up 2.326%.
Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
Currently, no hedge funds are holding shares in HK:3681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology